Mirati’s Adagrasib Challenger Fails To Differentiate Itself From Amgen’s Lumakras

 
• By Ayisha Sharma
  
Adagrasib Must Stand Out From The Crowd If It Wants Market Success • Source: Shutterstock

More from Clinical Trials

More from R&D